ID   VM-CUB-3
AC   CVCL_9830
SY   VM-CUB3; VMCUB-3; VMCUB3; VMCub3; VM Cub 3; VM-CUB-III; VMCUBIII; CUB III; CUBIII
DR   ATCC; HTB-6
DR   BioSample; SAMN03152040
DR   cancercelllines; CVCL_9830
DR   Cosmic; 925826
DR   Cosmic; 1016888
DR   Cosmic; 1046679
DR   Cosmic; 1285135
DR   Cosmic; 1285994
DR   Cosmic; 1938425
DR   Cosmic; 2050472
DR   Cosmic; 2057463
DR   Cosmic; 2444225
DR   Cosmic; 2212697
DR   GEO; GSM136263
DR   GEO; GSM1574580
DR   IARC_TP53; 6611
DR   Wikidata; Q54993215
RX   PubMed=571047;
RX   PubMed=3518877;
RX   PubMed=3708594;
RX   PubMed=6220172;
RX   PubMed=6244232;
RX   PubMed=7459858;
RX   PubMed=15846775;
RX   PubMed=16885334;
RX   PubMed=20143388;
RX   PubMed=24035680;
RX   PubMed=24367658;
RX   PubMed=25997541;
RX   PubMed=26621286;
RX   PubMed=27270441;
RX   PubMed=29732388;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
WW   https://www.synapse.org/UC25
CC   Problematic cell line: Partially contaminated. Some stocks are contaminated by VM-CUB-1 (PubMed=3708594; PubMed=20143388). Although PubMed=26621286 shows it to be different from VM-CUB-1.
CC   Part of: BLA-40 bladder carcinoma cell line panel.
CC   Part of: UBC-40 urothelial bladder cancer cell line index.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00102.
CC   Doubling time: 26 hours (PubMed=3708594).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Leu (c.833C>T); ClinVar=VCV000232497; Zygosity=Homozygous (PubMed=27270441).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: ATCC; HTB-6; true.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): PubMed=27270441
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 9,12
ST   D16S539: 12
ST   D5S818: 11
ST   D7S820: 8,9
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 16
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 30
//
RX   PubMed=571047;
RA   Fogh J.;
RT   "Cultivation, characterization, and identification of human tumor
RT   cells with emphasis on kidney, testis, and bladder tumors.";
RL   Natl. Cancer Inst. Monogr. 49:5-9(1978).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=3708594;
RA   Masters J.R.W., Hepburn P.J., Walker L., Highman W.J.,
RA   Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.N.,
RA   Franks L.M.;
RT   "Tissue culture model of transitional cell carcinoma: characterization
RT   of twenty-two human urothelial cell lines.";
RL   Cancer Res. 46:3630-3636(1986).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=6244232;
RA   Williams R.D.;
RT   "Human urologic cancer cell lines.";
RL   Invest. Urol. 17:359-363(1980).
//
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
//
RX   PubMed=15846775; DOI=10.1002/gcc.20166;
RA   Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J.M.,
RA   Knowles M.A.;
RT   "Assessment by M-FISH of karyotypic complexity and cytogenetic
RT   evolution in bladder cancer in vitro.";
RL   Genes Chromosomes Cancer 43:315-328(2005).
//
RX   PubMed=16885334; DOI=10.1158/0008-5472.CAN-06-1182;
RA   Lopez-Knowles E., Hernandez S., Malats N., Kogevinas M., Lloreta J.,
RA   Carrato A., Tardon A., Serra C., Real F.X.;
RT   "PIK3CA mutations are an early genetic alteration associated with
RT   FGFR3 mutations in superficial papillary bladder tumors.";
RL   Cancer Res. 66:7401-7404(2006).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057;
RA   Hurst C.D., Platt F.M., Knowles M.A.;
RT   "Comprehensive mutation analysis of the TERT promoter in bladder
RT   cancer and detection of mutations in voided urine.";
RL   Eur. Urol. 65:367-369(2014).
//
RX   PubMed=24367658; DOI=10.1371/journal.pone.0084411;
RA   Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H.,
RA   Knowles M.A.;
RT   "Identification of mutations in distinct regions of p85 alpha in
RT   urothelial cancer.";
RL   PLoS ONE 8:E84411-E84411(2013).
//
RX   PubMed=25997541; DOI=10.1186/s12864-015-1450-3;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "The UBC-40 Urothelial Bladder Cancer cell line index: a genomic
RT   resource for functional studies.";
RL   BMC Genomics 16:403.1-403.16(2015).
//
RX   PubMed=26621286; DOI=10.1186/s12864-015-2227-4;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a
RT   genomic resource for functional studies.";
RL   BMC Genomics 16:1019.1-1019.2(2015).
//
RX   PubMed=27270441; DOI=10.1038/onc.2016.172;
RA   Nickerson M.L., Witte N., Im K.M., Turan S., Owens C., Misner K.,
RA   Tsang S.X., Cai Z., Wu S., Dean M., Costello J.C., Theodorescu D.;
RT   "Molecular analysis of urothelial cancer cell lines for modeling tumor
RT   biology and drug response.";
RL   Oncogene 36:35-46(2017).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//